Flow cytometrical DNA- and clinical parameters in the prediction of prognosis in stage I-II endometrial carcinoma.
In almost all studies regarding flow cytometry and endometrial carcinoma, the DNA factors used are stronger prognostic parameters than the clinical factors previously used. Number of sub-populations and/or percentage of cells in S-phase are mostly used to select those tumors with the worst prognosis. In this study, reporting the 2 year follow-up of 245 patients (222 followed for more than 2 years), we claim that the DNA-index is a stronger prognostic tool than other DNA parameters, but also that the range of myometrial invasion is a stronger predictor than all other parameters including the DNA. Range of myometrial invasion and DNA index are used to form one high-risk group, consisting of 22% of the patients with a relapse rate of 38%, and one low-risk group, consisting of 47% of the patients with a relapse rate of 4%.